MTL

Team & Advisors

The people doing the evaluating

An evaluation is only as good as the judgment behind it. This bench was assembled for exactly one purpose: producing evidence about medtech throughput that holds up — to your leadership, to regulators’ standards of rigor, and to the people who built the technology being evaluated.

The team

Who runs the evaluations

Shannon Lantzy, PhD

Founder & Chief Executive

Shannon is a decision scientist who has spent her career on one question: what evidence does it take to move a high-stakes decision? She has designed and run independent evaluations across federal science and health programs and spent a decade in medtech R&D strategy. She hosts Inside Medtech Innovation, a podcast in conversation with the field's builders and regulators, and founded Medtech Throughput Labs to give manufacturers an honest, independent read on throughput technology.

For your team: The evaluation design — and the guarantee that its incentive is a fair answer, not a sale.

Sara Eggers, PhD

Benefit-Risk Decision Analyst

Sara is a decision scientist and former FDA leader in structured benefit-risk assessment, where she shaped how the Agency and medical product developers frame and analyze benefit-risk decisions for medical products. At MTL she owns the discipline that makes evaluation evidence decision-grade: framing the decision, defining criteria, analyzing uncertainty — and building confidence in the answer, including “this one isn't a fit.”

14 years at FDA's Center for Drug Evaluation and Research, including as Director, Decision Support and Analysis Staff. PhD in Engineering and Public Policy, Carnegie Mellon University.

For your team: Evidence structured the way regulators and executives actually decide — defensible, transparent, repeatable.

Jessica Mavadia-Shukla, PhD

Regulatory Advisor

Jessica is a former FDA reviewer and former FDA Program Manager for the Medical Device Development Tools (MDDT) Qualification Program — the agency's pathway for qualifying the tools that generate device evidence. She advises manufacturers and innovators on practical regulatory strategy: what evidence to generate, how to prepare a submission, and how to approach FDA.

For your team: A clear line of sight from evaluation evidence to what FDA-grade scrutiny will expect of it.

Aurora Bristor

Program Coordinator

Aurora is a systems thinker and risk analyst at home in highly complex systems. At MTL she runs the orchestration: the structure, sequencing, and safeguards that let a small expert bench evaluate deeply — across manufacturers, performers, and regulatory requirements — and create an integrated, persuasive case.

12 years at Fannie Mae, including as Director, Analytics & Modeling for Affordable Housing. MS in Applied Mathematics, University of Maryland.

For your team: An evaluation that respects your calendar — prepared meetings, bounded asks, and nothing re-invented on your time.

David Anderson, PhD

Analytics Lead

David is a professor of operations research whose work spans optimization and healthcare analytics. At MTL he leads the quantitative side of the bench — the statistical modeling behind benchmarks and ROI estimates — and builds the tooling that keeps analyses reproducible.

For your team: Numbers that survive a hard look — every model inspectable, every assumption written down.

Advisors

The advisory bench

Bob Gabbay, MD, PhD

Endocrinologist and diabetes-care leader affiliated with Harvard Medical School and the Joslin Diabetes Center. Bob advises MTL on clinical reality: what device software actually has to deliver for the people who depend on it.

Lane Desborough

Systems engineer and a defining figure in automated insulin delivery, with leadership roles across diabetes technology and a career grounded in industrial process control. Affiliated with AIDIF, he advises MTL on what throughput looks like from inside a device program that ships — and is working on a critical element of throughput: clinical validation with in-silico evidence.

Rob Allegar

Rob advises MTL on program strategy and business economics, and co-hosts a podcast with Shannon.

Deb Kilpatrick, PhD

Medtech executive and company builder — co-founder and former co-CEO of Evidation Health, with earlier commercial leadership in diagnostics and a PhD in engineering. Deb advises MTL on what it takes for evidence to carry weight in a commercial decision.

Partners

Organizations MTL works with to deliver evaluations

  • ArgusEye an AI-native product-security platform for medical devices and OT products.
  • Hubbard Decision Research (HDR) quantitative decision-analysis and measurement experts; brings statistical modeling and forecasting depth to MTL evaluations.
  • Basil Systems medtech post-market intelligence for medical device manufacturers and regulators.

Separately, Karambit.AI and Galois are candidate technologies under independent evaluation — ARPA-H-funded performers whose tools MTL evaluates on manufacturers’ behalf. They are not partners, and their evaluation is not an endorsement.

Talk to us

Put your questions to Shannon directly

A 20–30 minute briefing with the person who designed the evaluation. Bring your hardest questions — they make it better.